Maximus, Inc. (MMS) Stock Price & How to Invest

Maximus is a tech-enabled services company whose customer is almost entirely the government. Its three segments are U.S. Federal Services (~$721 million of revenue in the June 2026 quarter), U.S. Services (~$418 million) and Outside the U.S. (~$140 million). Work spans call centers and eligibility processing for Medicaid, CHIP and the ACA marketplaces, medical disability examinations for the Department of Veterans Affairs, employment and welfare-to-work programs in the United Kingdom, and a growing block of automation and AI-enabled case handling. Federal agencies supplied roughly 55 percent of trailing revenue, state agencies roughly a third (New York alone is about 11 percent), and international governments about 11 percent. Just under 60 percent of revenue sits on performance-based contracts, which is where both the margin upside and the volume risk live.

The investment picture is unusually stark. Over the twelve months to June 2026 Maximus earned ~$371 million of net income on ~$5.25 billion of revenue, expanded operating margin, bought back stock and raised the dividend, yet the shares fell roughly 31 percent over the past year and now change hands near ~8 times trailing earnings and under ~7 times forward guidance. Bears point at the customer concentration: a single directive from Washington or a state legislature can reprice a program overnight, as the temporary contract modification on a major federal program (guided at roughly $0.35 per share per quarter through the December 2026 period) demonstrated in August 2026. Bulls counter that revenue guidance was reiterated at $5.2 billion to $5.35 billion, free cash flow guidance sits at $425 million to $475 million, and a company converting that much of its profit to cash rarely trades at half of sales for long. Which view is right depends on whether the current federal spending posture is a cycle or a regime change.

Customer concentration is the defining exposure: federal and state agencies supply essentially all revenue, and the August 2026 guidance cut came not from lost business but from a customer-directed contract modification on one major federal program worth about $0.35 per share per quarter. Program-level policy shifts affecting Medicaid, CHIP or the ACA marketplaces can move whole segments without any operational failure at Maximus. On the legal side, Maximus Federal Services is a defendant in consumer class actions arising from the 2023 MOVEit file-transfer breach, now centralized as a multidistrict litigation in the District of Massachusetts where the company was named a bellwether defendant; roughly half the claims against it survived a July 2025 motion to dismiss and are in discovery, a related Florida state action (Taylor v. Maximus Federal Services) is stayed, and an amount has been accrued. No pending securities-fraud class action is disclosed in the Legal Proceedings item of the latest 10-Q. Leverage is meaningful, with gross debt of ~$1.65 billion after a $325 million term loan upsize in May 2026, and the Outside the U.S. segment is only guided to break even for the full year.

We give no verdict on Maximus, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Margin expansion from automation, not from growth. Revenue has been flat to down, but operating margin moved from ~9.7 percent in fiscal 2025 to ~11.0 percent on a trailing basis, and third-quarter operating margin reached 12.6 percent.

The case against. Customer concentration is the defining exposure: federal and state agencies supply essentially all revenue, and the August 2026 guidance cut came not from lost business but from a customer-directed contract modification on one major federal program worth about $0.35 per share per quarter.

Read the full bull and bear case on MMS, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Maximus, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$5.25B
• Net income (TTM): ~$371M
• Diluted EPS (TTM): ~$6.77
• Market cap: ~$2.90B
• P/E (trailing / forward): ~8.2x / ~6.7x
• Free cash flow (TTM): ~$433M

Fiscal 2026 guidance calls for revenue of ~$5.2B to ~$5.35B, adjusted diluted EPS of ~$7.90 to ~$8.20, adjusted EBITDA margin near 13.7 percent and free cash flow of ~$425M to ~$475M. At roughly ~0.56 times sales and ~6.5 times EV/EBITDA on an enterprise value near ~$4.57B, the market is applying a valuation more typical of a declining business than of one guiding to record adjusted earnings. Reconciling those two requires a view on federal contracting policy rather than on the income statement.

Other names that sit close to MMS: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get MMS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so MMS sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where MMS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Maximus is a profitable, cash-generative government outsourcer priced as if its federal and state contract base is about to shrink, and the gap between those two facts is the entire argument over the stock.

Whether MMS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MMS a buy or a sell?, and where the stock could go from here in the MMS stock forecast.

For income investors, whether MMS pays a dividend and how the payout looks is covered in does MMS pay a dividend? And to weigh MMS against a peer, read the full side-by-side comparisons: MMS vs LDOS and MMS vs BAH.